phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"phgenomics-10Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОГЕНЕТИКАCLINICAL PHARMACOGENETICSОценка эффективности антикоагулянтной терапии варфарином у детей с искусственными клапанами сердца в соответствии с исследованием вариабельности рецепторов генов VKORC1 и CYP2C9ЖиленковаА. В.noemail@neicon.ruТарнаеваЛ. А.noemail@neicon.ruФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)Russian Federation201712122017021616Copyright © Жиленкова А.В., Тарнаева Л.А., 20172017Жиленкова А.В., Тарнаева Л.А.Жиленкова А.В., Тарнаева Л.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/10полиморфизм CYP2C9полиморфизм VKORC1варфариндетиимплантация искусственных клапановReferencesMarek E., Momper J.D., Hines R.N., Takao C.M., Gill J.C., Pravica V. et al. Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. J Pediatr Pharmacol Ther. 2016;21(3): 224-232.Marek E., Momper J.D., Hines R.N., Takao C.M., Gill J.C., Pravica V. et al. Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. J Pediatr Pharmacol Ther. 2016;21(3): 224-232.Shaw K., Amstutz U., Hildebrand C., Rassekh S.R., Hosking M., Neville K. et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014;61(6): 1055-1062.Shaw K., Amstutz U., Hildebrand C., Rassekh S.R., Hosking M., Neville K. et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014;61(6): 1055-1062.Takeuchi M., Kobayashi T., Brandão L.R. Effect of CYP2C9, VKORC1 and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Syst Rev. 2016 23;5(1): 105.Takeuchi M., Kobayashi T., Brandão L.R. Effect of CYP2C9, VKORC1 and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Syst Rev. 2016 23;5(1): 105.
The authors declare that there are no conflicts of interest present.